HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

APYX

Apyx Medical Corporation (NASDAQ)

Healthcare — Medical Devices

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

None 4 analysts
$4.49
$0.17 (-4.26%)
Target: $6.50 (44.8%)
Sign in to add APYX to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$188.01M
P/E Ratio (TTM)-
Forward P/E-17.10
EPS (TTM)$-0.22
Dividend Yield-
Profit Margin-16.40%
Revenue Growth32.50%
ROE-76.49%
Debt/Equity301.51
Recommendation None
Analyst Target$6.50
Analysts4
Indexes NASDAQ

Technical Indicators

RSI (14)40.8
Beta1.39
SMA 20-
SMA 40-
52-Week High$5.08
52-Week Low$1.59
50-Day Avg$3.98
200-Day Avg$3.61
Avg Volume177.3K
Volume195.5K

Performance Analysis

BULLISH

APYX shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 83% of its 52-week range.
~ RSI at 40.8 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 32.5% year-over-year.
- Operating at a loss with -16.4% margin.
~ Wall Street consensus is "none" from 4 analysts.
+ Average analyst target of $6.50 implies 44.8% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jun 30, 2026 21:07 UTC

Back to Screener Export Report